Clinical-stage biotech
Appears in 1 story
Developer of zemprocitinib (LNK01001)
Roughly a third of rheumatoid arthritis patients don't get adequate relief from biologic drugs, the standard treatment after methotrexate. Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib kept 91.8% of those patients at an ACR20 response through 76 weeks.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
